Steven Cohen's position in Alnylam Pharmaceuticals is currently worth $12.4 Million. That's 0.04% of their equity portfolio (484th largest holding). The first Alnylam Pharmaceuticals trade was made in Q3 2014. Since then Steven Cohen bought shares nine more times and sold shares on ten occasions. The investor's estimated purchase price is $14.6 Million, resulting in a loss of 16%.